Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma

Cristiana Perrotta, Laura Bizzozero, Sestina Falcone, Patrizia Rovere-Querini, Alessandro Prinetti, Edward H. Schuchman, Sandro Sonnino, Angelo A. Manfredi, Emilio Clementi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Cisplatin is one of the most effective anticancer drugs, but its severe toxic effects, including depletion of immune-competent cells, limit its efficacy. We combined the systemic treatment with cisplatin with intratumor delivery of dendritic cells (DC) previously treated ex vivo with a pulse of nitric oxide (NO) released by the NO donors (z)-1-[2-(2-aminoethyl)-N-(2- ammonioethyl)amino]-diazen-1-ium-1,2-diolate or isosorbide dinitrate. We found that this chemoimmunotherapy, tested in the B16 mouse model of melanoma, was significantly more efficacious than cisplatin alone, leading to tumor regression and animal survival at low doses of cisplatin that alone had no effect. Tumor cure was not observed when combining cisplatin with DCs not exposed to NO donors, indicating the key role of the pretreatment with NO. We investigated the mechanisms responsible for the synergic effect of NO-treated DCs and cisplatin and found that NO-treated DCs were protected both in vitro and in vivo from cisplatin-induced cytotoxicity. Cisplatin triggered DC apoptosis through increased expression and activation of acid sphingomyelinase; pretreatment of DCs with NO donors prevented such activation and inhibited activation of the downstream proapoptotic events, including generation of ceramide, activation of caspases 3 and 9, and mitochondrial depolarization. The effects of NO were mediated through generation of its physiologic messenger, cyclic GMP. We conclude that NO and NO gener ating drugs represent promising tools to increase the efficacy of chemoimmunotherapies in vivo, promoting the survival and increasing the function of injected cells by targeting a key pathway in cisplatin-induced cytotoxicity.

Original languageEnglish
Pages (from-to)7559-7564
Number of pages6
JournalCancer Research
Volume67
Issue number16
DOIs
Publication statusPublished - Aug 15 2007

Fingerprint

Sphingomyelin Phosphodiesterase
Cisplatin
Melanoma
Nitric Oxide
Acids
Nitric Oxide Donors
Dendritic Cells
Isosorbide Dinitrate
Caspase 9
Ceramides
Poisons
Cyclic GMP
Caspase 3
Pharmaceutical Preparations
Neoplasms
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. / Perrotta, Cristiana; Bizzozero, Laura; Falcone, Sestina; Rovere-Querini, Patrizia; Prinetti, Alessandro; Schuchman, Edward H.; Sonnino, Sandro; Manfredi, Angelo A.; Clementi, Emilio.

In: Cancer Research, Vol. 67, No. 16, 15.08.2007, p. 7559-7564.

Research output: Contribution to journalArticle

Perrotta, Cristiana ; Bizzozero, Laura ; Falcone, Sestina ; Rovere-Querini, Patrizia ; Prinetti, Alessandro ; Schuchman, Edward H. ; Sonnino, Sandro ; Manfredi, Angelo A. ; Clementi, Emilio. / Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. In: Cancer Research. 2007 ; Vol. 67, No. 16. pp. 7559-7564.
@article{04859a07bc894cc4961f062996ede0c3,
title = "Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma",
abstract = "Cisplatin is one of the most effective anticancer drugs, but its severe toxic effects, including depletion of immune-competent cells, limit its efficacy. We combined the systemic treatment with cisplatin with intratumor delivery of dendritic cells (DC) previously treated ex vivo with a pulse of nitric oxide (NO) released by the NO donors (z)-1-[2-(2-aminoethyl)-N-(2- ammonioethyl)amino]-diazen-1-ium-1,2-diolate or isosorbide dinitrate. We found that this chemoimmunotherapy, tested in the B16 mouse model of melanoma, was significantly more efficacious than cisplatin alone, leading to tumor regression and animal survival at low doses of cisplatin that alone had no effect. Tumor cure was not observed when combining cisplatin with DCs not exposed to NO donors, indicating the key role of the pretreatment with NO. We investigated the mechanisms responsible for the synergic effect of NO-treated DCs and cisplatin and found that NO-treated DCs were protected both in vitro and in vivo from cisplatin-induced cytotoxicity. Cisplatin triggered DC apoptosis through increased expression and activation of acid sphingomyelinase; pretreatment of DCs with NO donors prevented such activation and inhibited activation of the downstream proapoptotic events, including generation of ceramide, activation of caspases 3 and 9, and mitochondrial depolarization. The effects of NO were mediated through generation of its physiologic messenger, cyclic GMP. We conclude that NO and NO gener ating drugs represent promising tools to increase the efficacy of chemoimmunotherapies in vivo, promoting the survival and increasing the function of injected cells by targeting a key pathway in cisplatin-induced cytotoxicity.",
author = "Cristiana Perrotta and Laura Bizzozero and Sestina Falcone and Patrizia Rovere-Querini and Alessandro Prinetti and Schuchman, {Edward H.} and Sandro Sonnino and Manfredi, {Angelo A.} and Emilio Clementi",
year = "2007",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-07-0309",
language = "English",
volume = "67",
pages = "7559--7564",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma

AU - Perrotta, Cristiana

AU - Bizzozero, Laura

AU - Falcone, Sestina

AU - Rovere-Querini, Patrizia

AU - Prinetti, Alessandro

AU - Schuchman, Edward H.

AU - Sonnino, Sandro

AU - Manfredi, Angelo A.

AU - Clementi, Emilio

PY - 2007/8/15

Y1 - 2007/8/15

N2 - Cisplatin is one of the most effective anticancer drugs, but its severe toxic effects, including depletion of immune-competent cells, limit its efficacy. We combined the systemic treatment with cisplatin with intratumor delivery of dendritic cells (DC) previously treated ex vivo with a pulse of nitric oxide (NO) released by the NO donors (z)-1-[2-(2-aminoethyl)-N-(2- ammonioethyl)amino]-diazen-1-ium-1,2-diolate or isosorbide dinitrate. We found that this chemoimmunotherapy, tested in the B16 mouse model of melanoma, was significantly more efficacious than cisplatin alone, leading to tumor regression and animal survival at low doses of cisplatin that alone had no effect. Tumor cure was not observed when combining cisplatin with DCs not exposed to NO donors, indicating the key role of the pretreatment with NO. We investigated the mechanisms responsible for the synergic effect of NO-treated DCs and cisplatin and found that NO-treated DCs were protected both in vitro and in vivo from cisplatin-induced cytotoxicity. Cisplatin triggered DC apoptosis through increased expression and activation of acid sphingomyelinase; pretreatment of DCs with NO donors prevented such activation and inhibited activation of the downstream proapoptotic events, including generation of ceramide, activation of caspases 3 and 9, and mitochondrial depolarization. The effects of NO were mediated through generation of its physiologic messenger, cyclic GMP. We conclude that NO and NO gener ating drugs represent promising tools to increase the efficacy of chemoimmunotherapies in vivo, promoting the survival and increasing the function of injected cells by targeting a key pathway in cisplatin-induced cytotoxicity.

AB - Cisplatin is one of the most effective anticancer drugs, but its severe toxic effects, including depletion of immune-competent cells, limit its efficacy. We combined the systemic treatment with cisplatin with intratumor delivery of dendritic cells (DC) previously treated ex vivo with a pulse of nitric oxide (NO) released by the NO donors (z)-1-[2-(2-aminoethyl)-N-(2- ammonioethyl)amino]-diazen-1-ium-1,2-diolate or isosorbide dinitrate. We found that this chemoimmunotherapy, tested in the B16 mouse model of melanoma, was significantly more efficacious than cisplatin alone, leading to tumor regression and animal survival at low doses of cisplatin that alone had no effect. Tumor cure was not observed when combining cisplatin with DCs not exposed to NO donors, indicating the key role of the pretreatment with NO. We investigated the mechanisms responsible for the synergic effect of NO-treated DCs and cisplatin and found that NO-treated DCs were protected both in vitro and in vivo from cisplatin-induced cytotoxicity. Cisplatin triggered DC apoptosis through increased expression and activation of acid sphingomyelinase; pretreatment of DCs with NO donors prevented such activation and inhibited activation of the downstream proapoptotic events, including generation of ceramide, activation of caspases 3 and 9, and mitochondrial depolarization. The effects of NO were mediated through generation of its physiologic messenger, cyclic GMP. We conclude that NO and NO gener ating drugs represent promising tools to increase the efficacy of chemoimmunotherapies in vivo, promoting the survival and increasing the function of injected cells by targeting a key pathway in cisplatin-induced cytotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=34548052207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548052207&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-0309

DO - 10.1158/0008-5472.CAN-07-0309

M3 - Article

VL - 67

SP - 7559

EP - 7564

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 16

ER -